• lianatech.fi
Tilaa tiedotesyöte Tilaa tiedotekooste Kirjaudu sisään
LianaPress LianaPress
  • Tiedotteet
  • Uutishuoneet
  • Osta tiedotteita
  • Tilaa tiedotteita
  • Tietoa palvelusta
  • Yhteydenotto
LianaPress
  • Tiedotteet
  • Uutishuoneet
  • Osta tiedotteita
  • Tilaa tiedotteita
  • Tietoa palvelusta
  • Yhteydenotto
Kirjaudu sisään
Tilaa tiedotesyöte Tilaa tiedotekooste

Sosiaalinen media

Seuraa ePressiä sosiaalisessa mediassa ja tilaa uutissyöte suoraan palveluun.

Facebook
Twitter
Facebook Twitter
Arcensus

Arcensus has appointed Prof. Dr. Arndt Rolfs as New CEO

Arcensus
13.1.2022, 09:43

 

 

NEW JERSEY, United States, ROSTOCK, Germany, and BERLIN, Germany – (EMAILWIRE) & (ARAB NEWSWIRE) -- Arcensus, a commercial-stage digital healthcare and diagnostics company that empowers people to take control of their health is pleased to announce that our Founder, Prof. Dr. Arndt Rolfs, a multi-entrepreneur in biotech and former CEO of several innovative biotech companies, including Nasdaq-listed company CENTOGENE, has been appointed as the Chief Executive Officer of Arcensus GmbH.

prof.-dr.-arndt-rolfs-ceo-arcensus-gmbh-2.jpeg

Prof. Rolfs has succeeded the role from Mr. Michael Schlenk and assumed the responsibilities of CEO on January 01, 2022. We are very grateful for the hard work and dedication of Mr. Schlenk for successfully performing the duties of CEO in 2021 and constructing the organization of Arcensus. We are reassured that Mr. Schlenk will continue supporting Arcensus as an active member of our supervisory board.

Mr Schlenk wished the new CEO every success: "I wish Arndt and the operational team all the best for 2022. There is no doubt that this year will bring great progress for Arcensus after building the company so successfully in a record time. I look forward to supporting the shaping of the business model as a member of the Supervisory Board."

Prof Rolfs is an experienced biotech entrepreneur who knows the necessities and challenges of the healthcare industry very well. Under his leadership, Arcensus will disrupt the genetic diagnostics market through the rapid expansion of its global genomic service and develop new concepts based on genomic knowledge generated worldwide. Arcensus' genomic data already has a diagnostic yield of about 80% in all genetically suspect patients.

Prof Rolfs said: "Our expertise in the high-quality interpretation of Whole Genome DNA Sequencing data reflects the next revolution in modern medicine. Our global genomic knowledge will help pharma partners accelerate the development of new drugs, especially for rare diseases."

BiotekniikkaKemianteollisuusTalousTerveysTiede ja tutkimusUlkomaat

Ladattavat tiedostot

prof.-dr.-arndt-rolfs-ceo-arcensus-gmbh.jpeg

Koko: 0,02 MB Tyyppi: jpeg Resoluutio: 320x213

Lataa tiedosto

prof.-dr.-arndt-rolfs-ceo-arcensus-gmbh.jpeg

Koko: 0,02 MB Tyyppi: jpeg Resoluutio: 320x213

Lataa tiedosto


Tietoa julkaisijasta

About Arcensus

Arcensus is a digital healthcare and diagnostics company that empowers people to take control of their health. The company provides a highest-standard, secure, trusted, and comprehensive medical service based on Whole Genome Sequencing. Arcensus analyses the complete genetic information in human DNA and identifies the predispositions as well as reasons for unclear symptoms with the help of cutting-edge technology including artificial intelligence. The detailed medical report suggests better treatment options and helps individuals take preventive measures to live a healthier and longer life.

From our offices in New Jersey – United States, Rostock and Berlin - Germany, a cross-functional team of genetic experts, medical doctors, and data scientists works to make the most sophisticated and best genetic interpretation with medical and health prevention applications accessible to everyone.

For more information, visit https://arcensus-diagnostics.com/

Important Notice and Disclaimer

This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws. Statements contained herein that are not clearly historical in nature are forward-looking, and the words “anticipate,” “believe,” “continues,” “expect,” “estimate,” “intend,” “project,” and similar expressions and future or conditional verbs such as “will,” “would,” “should,” “could,” “might,” “can,” and “may,” are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Arcensus’ actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates, our ability to streamline cash usage, our requirement for additional financing and our ability to continue as a going concern, or other factors.

 

Media Contact:
Arcensus GmbH
Awais Bhatti
+49 1525 7692031
[email protected]


The press release is issued through EmailWire.Com – a global newswire with press release distribution services.  For more information, go to  https://europenewswire.net/arcensus-has-appointed-prof-dr-arndt-rolfs-as-new-ceo/

Arcensus

Arcensus

Julkaisijan uutishuone

Julkaisijan viimeisimmät tiedotteet

Toimialan viimeisimmät tiedotteet

Arcensus

Arcensus

ePressi.com

  • Tiedotteet
  • Uutishuoneet
  • Osta tiedotteita
  • Tilaa tiedotteita
  • Tietoa palvelusta
  • Yhteydenotto
  • Rekisteriseloste

Toimialat

  • Arkkitehtuuri (1386) Autot ja moottoripyörät (4346) Avustukset ja vapaaehtoistyö (5630) Biotekniikka (1069) Elektroniikka (3068) Elokuvat ja televisio (497) Energia (7843) Euroopan unioni (204) Fashion (607) Hallitus ja valtio (13504) Hanketiedotteet (5424) Historia (2205) Häiriötiedotteet (3460) Ilmailu (723) Juomateollisuus (797) Kauppa (10013)
  • Kaupungit ja kunnat (32582) Kemianteollisuus (1048) Kieli (24) Kiinteistöt (7835) Kotimaa (35092) Koulutus (19408) Kulttuuri ja taide (21931) Kustannustoiminta (5013) Käsityöt ja askartelu (1465) Laki (4048) Lemmikit (848) Lifestyle (11036) Liikennetilanne (948) Logistiikka ja liikenne (11909) Maanpuolustus (1604) Maaseutu (5488)
  • Maatalous (5094) Mainonta (3262) Markkinointi (7060) Matkailu (9794) Media (7003) Metalliteollisuus (1600) Metsätalous (3362) Musiikki ja viihde (8832) Ohjelmistoteollisuus (3704) Pankit ja rahoitus (2419) Paperiteollisuus (869) Perhe (8821) Politiikka (12340) Psykologia (710) Puutarha (1752) Puuteollisuus (727)
  • Pääuutinen (1607) Pörssitiedote (155) Rakentaminen (10863) Ruoka ja elintarvikkeet (7646) Sarjakuva ja kuvitus (557) Sisustaminen (2527) Sosiaaliset kysymykset (10052) Suunnittelu ja tekniikka (5672) Talous (23122) Taloustiede (593) Teknologia (5793) Telekommunikaatio (5719) Terveys (14881) Tiede ja tutkimus (13621) Tietokoneet (2274) Tietotekniikka (5402)
  • Tietoturva (889) Tuotanto (3527) Turvallisuus (6264) Työelämä (15438) Ulkomaat (3587) Urheilu (10692) Urheilu ja vapaa-aika (6957) Uskonto (4718) Vakuutus (1396) Valokuvaus (1146) Vapaa-aika (18271) Vastuullisuus (121) Veneily (1172) Ympäristö ja luonto (19664) Yrittäjyys (7833)
 
  • Avainlippu
  • AAA
  • European Busine...
  • Suomen yrittäjä...
  • Deloitte
  • iab
Social Media Social Media

© Koodiviidakko Oy - Y-tunnus 1939962-1